
Opinion|Videos|August 28, 2024
Advancing CML Management Towards an Ideal Patient Journey
The panel concludes its discussion with insights on challenges and unmet needs in the CML treatment landscape, highlighting ways to better support patients and caregivers.
Advertisement
Episodes in this series

This program was made possible with support from Novartis Pharmaceuticals.
Video content above is prompted by the following questions:
- What are the biggest unmet needs you see for CML patients today, and how do you think emerging therapies and research could address those gaps in the future?
- What excites you most about the potential advancements in CML management that may be on the horizon in the next 5-10 years?
- How do you envision the CML patient experience being transformed compared to today?
Advertisement
Related to this article

The supplement, sold in Europe as OnLife, was evaluated in the single-arm STEFANO study of 146 patients with paclitaxel- or oxaliplatin-induced CIPN.

The evERA principal investigator explains ESR1 testing, bradycardia and stomatitis prevention, and oral adherence with giredestrant plus everolimus.

Beth Sandy, MSN, CRNP, FAPO, reviewed ADCs, immunotherapy, and targeted therapy in NSCLC with a focus on what nurses should monitor.

Neladalkib produced response rates of 49% after alectinib and 32% after multiple ALK TKIs plus chemotherapy in the ALKOVE-1 trial.

JoAnne Page, RN, a breast cancer survivor, shares what oncology nurses can do for care partners of patients with bladder cancer.

Giredestrant (Wilserdly) plus everolimus nearly doubled median PFS vs standard endocrine therapy plus everolimus in ESR1-mutated disease in evERA.

Alembic's generic binimetinib, in 15 mg and 45 mg tablets, is therapeutically equivalent to Mektovi for BRAF-mutant melanoma and NSCLC.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Giredestrant Plus Everolimus for ESR1-Mutated Breast Cancer
2
FDA Grants Accelerated Approval to Neladalkib in Pretreated ALK+ NSCLC
3
FDA Declines Ivonescimab Approval in EGFR+ NSCLC Over Survival Data
4
FDA Approves Pertuzumab Biosimilar Pebrilzo for HER2+ Breast Cancer
5

